Zhai Kan, Yang Yong, Gao Zhi-Gang, Ding Jie
Medical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
Department of General Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
Oncotarget. 2017 Jul 4;8(27):44490-44497. doi: 10.18632/oncotarget.17771.
Interleukin-6 (IL-6) is known to be involved in the pathogenesis of cancer progression. IL-6-174G>C polymorphism has shown several results in association studies. In this study, we evaluated the association the IL-6-174G>C polymorphism and overall survival (OS) of cancer using 17 eligible studies with 4,304 patients. Our meta-analysis indicated that IL-6-174G>C polymorphism is not associated with OS when assessed using 3 genotype comparison including GG/(GC+CC), CC/(GC+GG) and CC/GG. Interestingly, compared to GG carrier, patients with IL-6-174GC genotype showed a decreased hazard of poor OS (hazard ratio = 0.81, 95% confidence interval: 0.68-0.96, P = 0.018; I2 = 34.5%, Phet = 0.107). However, for GG/(GC+CC) genotype comparison, this SNP is affect patients' OS obviously in bladder cancer, ovarian and peritoneal cancer, neuroblastoma, gastric cancer and osteosarcoma, though pooled results showing negative association because adverse and protective effect on different type of cancer balance each other. These results suggest IL-6-174G>C polymorphism might play a role in modulating OS in different type of cancer and might contribute to individual treatment in the future.
白细胞介素-6（IL-6）已知参与癌症进展的发病机制。IL-6 - 174G>C多态性在关联研究中已呈现出多种结果。在本研究中，我们使用17项符合条件的研究中的4304例患者，评估了IL-6 - 174G>C多态性与癌症总生存期（OS）之间的关联。我们的荟萃分析表明，当使用包括GG/（GC + CC）、CC/（GC + GG）和CC/GG在内的3种基因型比较进行评估时，IL-6 - 174G>C多态性与总生存期无关。有趣的是，与GG携带者相比，IL-6 - 174GC基因型患者的不良总生存期风险降低（风险比 = 0.81，95%置信区间：0.68 - 0.96，P = 0.018；I2 = 34.5%，Phet = 0.107）。然而，对于GG/（GC + CC）基因型比较，尽管汇总结果显示为负相关，但由于对不同类型癌症的不利和保护作用相互平衡，该单核苷酸多态性（SNP）在膀胱癌、卵巢癌和腹膜癌、神经母细胞瘤、胃癌和骨肉瘤中明显影响患者的总生存期。这些结果表明，IL-6 - 174G>C多态性可能在调节不同类型癌症的总生存期方面发挥作用，并可能在未来有助于个体化治疗。
